Press Releases April 27, 2026 06:03 AM

OwlTing Group (NASDAQ: OWLS) to Announce Full Year 2025 Financial Results

OwlTing Group to report full year 2025 financial results and hold a conference call on April 29-30, 2026

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
OWLS

OwlTing Group, a Nasdaq-listed global fintech company, announced it will release its financial results for the full year ended December 31, 2025 after the U.S. market closes on April 29, 2026. The company will also hold a management conference call on April 30 to discuss these results and recent business developments. OwlTing is recognized as a high-growth Asia-Pacific fintech firm operating in payments, hospitality and e-commerce sectors with a strong focus on digital currency solutions.

OwlTing Group (NASDAQ: OWLS) to Announce Full Year 2025 Financial Results
OWLS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • OwlTing Group will announce full year 2025 financial results on April 29, 2026.
  • Management will host a conference call on April 30, 2026 to discuss results and business updates.
  • The company operates globally in fintech, with a focus on digital currency payments and distributed ledger technology.
  • Sectors impacted: Financial Technology, Digital Currency, Payments, Hospitality, E-commerce markets.

ARLINGTON, Va., April 27, 2026 (GLOBE NEWSWIRE) -- OwlTing Group (NASDAQ: OWLS) (“OwlTing” or the “Company”), the operating brand of OBOOK Holdings Inc., a global fintech company, today announced that it will report its financial results for the full year ended December 31, 2025 after the U.S. market closes on April 29, 2026.

The Company’s management team will host a conference call to discuss the full year 2025 financial results and recent business developments. 

Details of the webcast are as follows:

Date and time: 08:30 a.m. Eastern Time on April 30, 2026

Webcast link:
https://events.zoom.us/ev/AnOTyvG3Y9wQqw7yacA9VQjKvLWbbWYm6dO2hlF57YILSooj7yYh~AjSbMXMkTEdNEL9hjRr-jVwZlMzSmshcyR15pmhcS5fKI_HPnegU4EWM2A

A live and archived webcast of the conference call will be available on the Company's Investor Relations website at https://investors.owlting.com/.

About OwlTing Group
OwlTing Group (NASDAQ: OWLS) is the operating brand of OBOOK Holdings Inc., a global fintech company founded in Taiwan, with subsidiaries in the United States, Japan, Poland, Singapore, Hong Kong, Thailand, and Malaysia. The Company operates a diversified ecosystem across payments, hospitality, and e-commerce. In 2026, OwlTing was named to the Financial Times and Statista “High-Growth Companies Asia-Pacific 2026” list, ranking No. 226 among the top 500 fastest-growing companies in the region with a 42% CAGR. In 2025, OwlTing was ranked among the top 2 global players for the "Enterprise & B2B" category in the digital currency sector by CB Insights statistics. The Company’s mission is to use distributed ledger technology to provide businesses with more reliable and transparent data management, to reinvent the global flow of funds for businesses and consumers, and to lead the digital transformation of business operations. To this end, the Company introduced OwlPay, a Web2 and Web3 hybrid payment solution, to empower global businesses to operate confidently in the expanding digital currency economy. For more information, visit https://www.owlting.com/portal/?lang=en.

For investor and media enquiries, please contact:

OwlTing Group Investor RelationsOwlTing Group Media RelationsHenry Fan, Investor Relations DirectorMichael Hsu, Public Relations Directorir@owlting.compr_office@owlting.com  The Blueshirt Group, Investor Relations Jack Wang, Managing Director OwlTing@BlueshirtGroup.co 



Risks

  • Financial results could underperform market expectations, affecting stock price and investor sentiment.
  • Global operational risks from multiple international subsidiaries across Asia, Europe, and the US may impact business outcomes.
  • Competitive challenges in the rapidly evolving fintech and digital currency sectors could pressure future growth.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026